We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-1.18%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$509M
AUM Growth
-$864K
Cap. Flow
+$29.1M
Cap. Flow %
5.72%
Top 10 Hldgs %
50.89%
Holding
58
New
16
Increased
12
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.6M
2
CYTK icon
Cytokinetics
CYTK
+$20.4M
3
ANAB icon
AnaptysBio
ANAB
+$19.2M
4
EOLS icon
Evolus
EOLS
+$18.1M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.4M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$20.6M
2
VTYX
Ventyx Biosciences
VTYX
+$13.1M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$12.5M
4
PTCT icon
PTC Therapeutics
PTCT
+$11.5M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
51
Sarepta Therapeutics
SRPT
$1.57B
– –
-73,000
Closed -$9.46M
VERV
52
DELISTED
Verve Therapeutics
VERV
– –
-300,000
Closed -$5.8M
VTYX
53
DELISTED
Ventyx Biosciences
VTYX
– –
-400,695
Closed -$13.1M
MRTX
54
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-133,000
Closed -$6.03M
SGEN
55
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-160,500
Closed -$20.6M
ICPT
56
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-528,850
Closed -$6.54M
ALBO
57
DELISTED
Albireo Pharma Inc
ALBO
– –
-267,283
Closed -$5.78M
CINC
58
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-1,019,153
Closed -$12.5M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Great Point Partners held 58 positions worth $509M, down 0.17% from $510M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Great Point Partners deployed $29.1M of net new capital in Q1 2023, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Cytokinetics: 500,000 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $8.35M trimmed.

  • Great Point Partners's largest Q1 2023 buy was Cytokinetics: 500,000 shares worth $17.6M.
  • Great Point Partners added most to Amylyx Pharmaceuticals in Q1 2023, an estimated $20.6M increase.
  • Great Point Partners's biggest Q1 2023 reduction was Cymabay Therapeutics, cutting an estimated $8.35M.
  • Great Point Partners fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $20.6M.
  • Great Point Partners's ten largest holdings make up 51% of its $509M portfolio in Q1 2023.
  • Great Point Partners opened 16 new positions and closed 14 in Q1 2023.
  • Great Point Partners's portfolio value fell 0.17% quarter-over-quarter to $509M.

Based on Great Point Partners's 13F filing for Q1 2023, filed 15 May 2023.